Research and development daily Xinda IBI112 initiated Phase I clinical ritual into a class 1 new drug in China reported clinical.

2020.08.13 Research and Development NEWS: AbbVievenetoclax combined with Azatrocyte first-line treatment AML significantly extended OS; We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original article) AbbVievenetoclax joint Aza cytoclix first-line therapy AML significantly extended OS12, AbbVie announced the results of Phase 3 clinical trial VIALE-A published in New England Medicine.
the study evaluated the efficacy and safety of venetoclax co-azatosine in patients with new diagnosed acute myeloid leukemia without chemotherapy and in patients who were not resistant to traditional high-intensity chemotherapy.
results showed that venetoclax dual-drug therapy significantly extended the total lifetime and reduced the risk of death by 34 percent compared to Azat and placebo combinations.
Xinda Bio1 new drug IBI112 initiated Phase I clinical 10, Xinda Bio in the drug clinical trial registration and information publicity platform registration launched a class 1 new drug IBI112 in health subjects of single-dose administration phase I clinical research.
research after the listing of Lenvima: 24 mg is the appropriate starting dose of differentiated thyroid cancer, the anti-cancer drug Lenvima treatment of radioactive iodine refractic differentiated thyroid cancer Phase II clinical results.
Lenvima, an oral polyceptamate tyrosine kinase inhibitor, compared the efficacy and safety of Lenvima's two starting doses (18 mg vs 24 mg, once daily).
data support the selection of 24 mg as the appropriate starting dose for patients with RAI resopathic DTC.
FDA accelerates approval of DMD innovative therapies today, the FDA announced accelerated approval of the listing of Viltepso, a subsidiary of NS Pharma, a subsidiary of Japan's New Drug Co., Ltd., for the treatment of specific patients with ductum muscular dystrophy (DMD).
Lijin bio-class 1 new drugs declared clinical in China on the 12th, CDE publicity, Lijin biological submitted a class 1 bio-new drug LVGN6051 monoclonal antibody injection clinical trial application, and was accepted.
Fosun Pharma Malay acid Avaquopa tablets were approved clinically today, Fosun Pharma announced that the company's controlling subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. received the "Receiving Notice", its licensed Malay acid Avalancopa tablets for chronic immunocompetitive plate plateboard reduction (ITP) by the State Drug Administration clinical trial registration review.
Treasure Island anti-idydynetic pulmonary fibrosis class 1 innovative drug ZBD0276 tablets were approved for clinical trials on the 12th, Heilongjiang Treasure Island Pharmaceuticals announced that the company received the "Drug Clinical Trial Approval Notice" for the anti-idydic pulmonary fibrosis class 1 innovative drug ZBD0276 tablets of clinical trial approval.
Domestic anti-AIDS class 1 new drug "Azf tablets" to be included in the priority review 12, CDE official website shows that Henan Real Biotechnology Co., Ltd. 1 new drugs "Azf tablets" listing applications to be included in the priority review, the reasons for clinical shortage of drugs, prevention and treatment of major infectious diseases and rare diseases and other diseases of innovative drugs and improved new drugs into the priority review process.
Tukysa has been approved to join the U.S. Oribis program by all regulators, Seattle Genetics, recently announced that the Australian Therapeutic Products Administration has approved targeted anti-cancer drugs Tukysa, co-cinnapressant and carpedabin for the treatment of patients with advanced or metastatic HER2-positive breast cancer who cannot be surgically removed and have previously received one or more anti-HER2 programs, including those with brain metastasis.
Xinlitai hydrochloric acid parositin intestinal dissolved release tablets are expected to take the first imitation recently, Xinlitai hydrochloric acid parositin intestinal dissolved release tablets 4 types of imitation market applications entered the "in the approval" stage, is expected to take the first imitation in the near future.
Hesco injection acetate capofen net will be reviewed recently, Hesco injection acetate carpofen net 6 imitation market application has entered the "in the approval" stage, is expected to usher in good news.
.